BR112012018951A2 - composição farmacêutica, combinação farmacêutica e método para o tratamento e\ou prevenção de um câncer e anticorpo - Google Patents
composição farmacêutica, combinação farmacêutica e método para o tratamento e\ou prevenção de um câncer e anticorpoInfo
- Publication number
- BR112012018951A2 BR112012018951A2 BR112012018951A BR112012018951A BR112012018951A2 BR 112012018951 A2 BR112012018951 A2 BR 112012018951A2 BR 112012018951 A BR112012018951 A BR 112012018951A BR 112012018951 A BR112012018951 A BR 112012018951A BR 112012018951 A2 BR112012018951 A2 BR 112012018951A2
- Authority
- BR
- Brazil
- Prior art keywords
- antibody
- treating
- preventing cancer
- pharmaceutical
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2010-023453 | 2010-02-04 | ||
JP2010023453 | 2010-02-04 | ||
JP2010-183116 | 2010-08-08 | ||
JP2010183161 | 2010-08-18 | ||
PCT/JP2011/052412 WO2011096533A1 (ja) | 2010-02-04 | 2011-02-04 | 癌の治療及び/又は予防用医薬組成物 |
Publications (5)
Publication Number | Publication Date |
---|---|
BR112012018951A2 true BR112012018951A2 (pt) | 2017-06-27 |
BR112012018951A8 BR112012018951A8 (pt) | 2020-03-31 |
BR112012018951B1 BR112012018951B1 (pt) | 2020-05-12 |
BR112012018951B8 BR112012018951B8 (pt) | 2020-06-09 |
BR112012018951C8 BR112012018951C8 (pt) | 2020-06-23 |
Family
ID=44355527
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112012018951A BR112012018951C8 (pt) | 2010-02-04 | 2011-02-04 | anticorpo monoclonal, composição farmacêutica, combinação farmacêutica, uso de um anticorpo, uso de uma composição farmacêutica e uso de uma combinação farmacêutica |
Country Status (16)
Country | Link |
---|---|
US (1) | US8937160B2 (pt) |
EP (1) | EP2532366B1 (pt) |
JP (1) | JP5742713B2 (pt) |
KR (1) | KR101801667B1 (pt) |
CN (1) | CN102821789B (pt) |
AU (1) | AU2011211698B2 (pt) |
BR (1) | BR112012018951C8 (pt) |
CA (1) | CA2788716C (pt) |
DK (1) | DK2532366T3 (pt) |
ES (1) | ES2606173T3 (pt) |
HU (1) | HUE030742T2 (pt) |
MX (1) | MX342291B (pt) |
PL (1) | PL2532366T3 (pt) |
PT (1) | PT2532366T (pt) |
RU (1) | RU2597971C2 (pt) |
WO (1) | WO2011096533A1 (pt) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2009278386B2 (en) | 2008-08-05 | 2015-05-21 | Toray Industries, Inc. | Pharmaceutical composition for treatment and prevention of cancers |
RU2519089C2 (ru) | 2008-08-05 | 2014-06-10 | Торэй Индастриз, Инк. | Способ обнаружения злокачественных опухолей |
CN102821788B (zh) | 2010-02-04 | 2016-11-16 | 东丽株式会社 | 癌的治疗和/或预防用药物组合物 |
PL2532743T3 (pl) | 2010-02-04 | 2015-09-30 | Toray Industries | Kompozycja farmaceutyczna do leczenia i/lub zapobiegania raka |
MX342291B (es) | 2010-02-04 | 2016-09-23 | Toray Industries | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. |
JP5923984B2 (ja) | 2010-02-04 | 2016-05-25 | 東レ株式会社 | 癌の治療及び/又は予防のための医薬品 |
AU2011211682B2 (en) | 2010-02-04 | 2015-08-13 | Toray Industries, Inc. | Pharmaceutical composition for treating and/or preventing cancer |
KR101758117B1 (ko) | 2010-02-04 | 2017-07-14 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방용 의약 조성물 |
WO2013018891A1 (ja) | 2011-08-04 | 2013-02-07 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
CA2844030C (en) | 2011-08-04 | 2019-09-03 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prophylaxis of cancer |
HUE033628T2 (en) | 2011-08-04 | 2017-12-28 | Toray Industries | Method for detecting pancreatic cancer |
US9409993B2 (en) | 2011-08-04 | 2016-08-09 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of pancreatic cancer |
CA2844034C (en) | 2011-08-04 | 2019-07-16 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prophylaxis of cancer |
PT2740793T (pt) | 2011-08-04 | 2018-02-23 | Toray Industries | Composição de fármacos para o tratamento e/ou a prevenção de cancro |
KR101979208B1 (ko) | 2011-08-04 | 2019-05-16 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방용 의약 조성물 |
JP6187258B2 (ja) * | 2012-02-21 | 2017-08-30 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
RU2632645C2 (ru) | 2012-02-21 | 2017-10-06 | Торэй Индастриз, Инк. | Фармацевтическая композиция для лечения и/или профилактики рака |
KR102005308B1 (ko) * | 2012-02-21 | 2019-07-30 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방용 의약 조성물 |
IN2014KN01715A (pt) | 2012-02-21 | 2015-10-23 | Toray Industries | |
US9416193B2 (en) | 2012-03-30 | 2016-08-16 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of liver cancer |
DK2832366T3 (en) | 2012-03-30 | 2018-01-22 | Toray Industries | PHARMACEUTICAL COMPOSITION FOR TREATMENT AND / OR PREVENTION OF Gallbladder cancer |
US9753038B2 (en) | 2012-07-19 | 2017-09-05 | Toray Industries, Inc. | Method for detecting cancer via measurement of caprin-1 expression level |
TR201902972T4 (tr) | 2012-07-19 | 2019-03-21 | Toray Industries | Kanseri tespit etmek için yöntem. |
EP3003390B1 (en) | 2013-06-06 | 2021-07-07 | Pierre Fabre Médicament | Anti-c10orf54 antibodies and uses thereof |
JP6447130B2 (ja) | 2013-08-09 | 2019-01-09 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
WO2018009916A1 (en) | 2016-07-07 | 2018-01-11 | The Board Of Trustees Of The Leland Stanford Junior University | Antibody adjuvant conjugates |
CA3041979A1 (en) | 2016-10-28 | 2018-05-03 | Toray Industries, Inc. | Pharmaceutical composition for cancer treatment and/or prevention |
EP3777888A4 (en) | 2018-03-30 | 2021-12-01 | Toray Industries, Inc. | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND / OR PREVENTION OF CANCER |
WO2020190725A1 (en) | 2019-03-15 | 2020-09-24 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting her2 |
CA3175279A1 (en) | 2020-03-12 | 2021-09-16 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
JPWO2021182571A1 (pt) | 2020-03-12 | 2021-09-16 | ||
EP4119159A4 (en) | 2020-03-12 | 2024-03-27 | Toray Industries | MEDICINE FOR THE TREATMENT AND/OR PREVENTION OF CANCER |
WO2021182570A1 (ja) | 2020-03-12 | 2021-09-16 | 東レ株式会社 | 癌の治療及び/又は予防のための医薬品 |
US20230129035A1 (en) | 2020-03-12 | 2023-04-27 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
KR20240024803A (ko) | 2021-06-23 | 2024-02-26 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방을 위한 의약품 |
AU2022296193A1 (en) | 2021-06-23 | 2024-01-18 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
WO2023008461A1 (ja) | 2021-07-27 | 2023-02-02 | 東レ株式会社 | 癌の治療及び/又は予防のための医薬品 |
KR20240041917A (ko) | 2021-07-27 | 2024-04-01 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방을 위한 의약품 |
AU2022319362A1 (en) | 2021-07-27 | 2024-02-29 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
WO2023033129A1 (ja) | 2021-09-03 | 2023-03-09 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
Family Cites Families (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
EP0770628B9 (en) | 1994-07-13 | 2007-02-28 | Chugai Seiyaku Kabushiki Kaisha | Reconstituted human antibody against human interleukin-8 |
US5698396A (en) | 1995-06-07 | 1997-12-16 | Ludwig Institute For Cancer Research | Method for identifying auto-immunoreactive substances from a subject |
FR2761994B1 (fr) | 1997-04-11 | 1999-06-18 | Centre Nat Rech Scient | Preparation de recepteurs membranaires a partir de baculovirus extracellulaires |
ES2364266T3 (es) | 1998-04-03 | 2011-08-30 | Chugai Seiyaku Kabushiki Kaisha | Anticuerpo humanizado hacia el factor tisular humano (tf) y procedimiento para construir el anticuerpo humanizado. |
US20030118599A1 (en) | 1999-04-02 | 2003-06-26 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
RU2234942C2 (ru) | 1998-07-14 | 2004-08-27 | Корикса Корпорейшн | Выделенный опухолевый полипептид предстательной железы и кодирующий его полинуклеотид |
KR20070112860A (ko) | 1998-07-14 | 2007-11-27 | 코릭사 코포레이션 | 전립선 종양 단백질의 분리된 면역원성 부위 및 이를사용하여 전립선암을 진단하는 방법 |
US6969518B2 (en) | 1998-12-28 | 2005-11-29 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of breast cancer |
WO2000052204A2 (en) | 1999-02-22 | 2000-09-08 | Orntoft Torben F | Gene expression in bladder tumors |
US6444425B1 (en) | 1999-04-02 | 2002-09-03 | Corixa Corporation | Compounds for therapy and diagnosis of lung cancer and methods for their use |
WO2000060077A2 (en) | 1999-04-02 | 2000-10-12 | Corixa Corporation | Compounds for therapy and diagnosis of lung cancer and methods for their use |
US6949245B1 (en) | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
EP1224285A4 (en) | 1999-10-29 | 2004-12-08 | Human Genome Sciences Inc | 27 HUMAN SECRETED PROTEINS |
US20020006404A1 (en) | 1999-11-08 | 2002-01-17 | Idec Pharmaceuticals Corporation | Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications |
PL366626A1 (en) | 2000-03-29 | 2005-02-07 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
ATE378403T1 (de) | 2000-11-30 | 2007-11-15 | Medarex Inc | Transchromosomale transgen-nagetiere zur herstellung von humänen antikörpern |
US7919467B2 (en) | 2000-12-04 | 2011-04-05 | Immunotope, Inc. | Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
US20040029114A1 (en) | 2001-01-24 | 2004-02-12 | Eos Technology, Inc. | Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer |
RU2306952C2 (ru) | 2001-01-31 | 2007-09-27 | Байоджен Айдек Инк. | Лечение в-клеточных злокачественных опухолей с использованием комбинации применений, связанных с антителами, уменьшающими количество b-клеток, и с иммуномодулирующими антителами |
AU2002311787A1 (en) | 2001-03-28 | 2002-10-15 | Zycos Inc. | Translational profiling |
WO2002083070A2 (en) * | 2001-04-10 | 2002-10-24 | Corixa Corporation | Compounds for immunotherapy and diagnosis of colon cancer and methods for their use |
CA2508763C (en) | 2001-05-11 | 2012-01-24 | Kirin Beer Kabushiki Kaisha | Human antibody producing mouse and method for producing human antibody using the same |
AU2002311909A1 (en) | 2001-05-11 | 2002-11-25 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
US20030190640A1 (en) | 2001-05-31 | 2003-10-09 | Mary Faris | Genes expressed in prostate cancer |
RU2319709C2 (ru) * | 2001-07-17 | 2008-03-20 | Рисерч Дивелопмент Фаундейшн | Терапевтические агенты, содержащие проапоптозные белки |
US20040142325A1 (en) | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
WO2003072035A2 (en) * | 2002-02-22 | 2003-09-04 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
US20050003390A1 (en) * | 2002-05-17 | 2005-01-06 | Axenovich Sergey A. | Targets for controlling cellular growth and for diagnostic methods |
US20040126379A1 (en) | 2002-08-21 | 2004-07-01 | Boehringer Ingelheim International Gmbh | Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and chemotherapeutic agents |
US20060121029A1 (en) | 2002-08-30 | 2006-06-08 | Hiroshi Shiku | Method and composition for regulating the activity of regulatory t cells |
EP2314676A1 (en) * | 2002-11-26 | 2011-04-27 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
WO2004076682A2 (en) | 2003-02-26 | 2004-09-10 | Surromed, Inc. | Targets for controlling cellular growth and for diagnostic methods |
AU2004235382A1 (en) | 2003-04-29 | 2004-11-11 | Wyeth | Methods for diagnosing AML and MDS differential gene expression |
JP2007516693A (ja) | 2003-06-09 | 2007-06-28 | ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガン | 癌の治療および診断のための組成物および方法 |
WO2005007830A2 (en) | 2003-07-14 | 2005-01-27 | Mayo Foundation For Medical Education And Research | Methods and compositions for diagnosis, staging and prognosis of prostate cancer |
US20050032113A1 (en) | 2003-07-17 | 2005-02-10 | Mitsubishi Pharma Corporation | Membrane protein library for proteome analysis and method for preparing same |
JP4734319B2 (ja) | 2004-03-19 | 2011-07-27 | イムクローン・リミテッド・ライアビリティ・カンパニー | ヒト抗上皮成長因子受容体抗体 |
RU2429245C2 (ru) | 2004-03-30 | 2011-09-20 | Глаксо Груп Лимитед | Иммуноглобулины |
WO2005100998A2 (en) | 2004-04-16 | 2005-10-27 | Europroteome Ag | Membrane markers for use in cancer diagnosis and therapy |
DE102004026135A1 (de) | 2004-05-25 | 2006-01-05 | Immatics Biotechnologies Gmbh | An MHC-Moleküle bindende Tumor-assoziierte Peptide |
WO2006002378A2 (en) | 2004-06-23 | 2006-01-05 | Avalon Pharmaceuticals | Determining cancer-linked genes and therapeutic targets using molecular cytogenetic methods |
US7449184B2 (en) | 2005-01-21 | 2008-11-11 | Genentech, Inc. | Fixed dosing of HER antibodies |
US7858324B2 (en) | 2005-02-18 | 2010-12-28 | Children's Medical Center Corporation | Cyr61 as a biomarker for diagnosis and prognosis of cancers of epithelial origin |
KR101310000B1 (ko) | 2005-03-11 | 2013-09-25 | 싸이퍼젠 바이오시스템즈, 인코포레이티드 | 난소암 및 자궁내막암에 대한 바이오마커 : 헵시딘 |
JP2006316040A (ja) | 2005-05-13 | 2006-11-24 | Genentech Inc | Herceptin(登録商標)補助療法 |
US8014957B2 (en) | 2005-12-15 | 2011-09-06 | Fred Hutchinson Cancer Research Center | Genes associated with progression and response in chronic myeloid leukemia and uses thereof |
CA2642342A1 (en) * | 2006-02-14 | 2007-08-23 | Dana-Farber Cancer Institute, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer |
US20100015724A1 (en) | 2006-08-17 | 2010-01-21 | Peter Hornbeck | Lysine acetylation sites |
US20080107668A1 (en) | 2006-08-30 | 2008-05-08 | Immunotope, Inc. | Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
US7615349B2 (en) | 2006-09-07 | 2009-11-10 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Melanoma gene signature |
WO2008059252A2 (en) | 2006-11-15 | 2008-05-22 | Oxford Biomedica (Uk) Limited | Methods and composition fro t cell receptors which recognize 5t4 antigen |
JP2010023453A (ja) | 2008-07-24 | 2010-02-04 | Seiko Epson Corp | 流体噴射装置のメンテナンス方法及び流体噴射装置 |
AU2009278386B2 (en) | 2008-08-05 | 2015-05-21 | Toray Industries, Inc. | Pharmaceutical composition for treatment and prevention of cancers |
KR101669827B1 (ko) | 2008-08-05 | 2016-10-27 | 도레이 카부시키가이샤 | 면역 유도제 |
RU2519089C2 (ru) * | 2008-08-05 | 2014-06-10 | Торэй Индастриз, Инк. | Способ обнаружения злокачественных опухолей |
JP2010183161A (ja) | 2009-02-03 | 2010-08-19 | Toshiba Corp | カメラシステム |
MX342291B (es) | 2010-02-04 | 2016-09-23 | Toray Industries | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. |
JP5923984B2 (ja) | 2010-02-04 | 2016-05-25 | 東レ株式会社 | 癌の治療及び/又は予防のための医薬品 |
CN102821788B (zh) | 2010-02-04 | 2016-11-16 | 东丽株式会社 | 癌的治疗和/或预防用药物组合物 |
PL2532743T3 (pl) | 2010-02-04 | 2015-09-30 | Toray Industries | Kompozycja farmaceutyczna do leczenia i/lub zapobiegania raka |
KR101758117B1 (ko) | 2010-02-04 | 2017-07-14 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방용 의약 조성물 |
AU2011211682B2 (en) | 2010-02-04 | 2015-08-13 | Toray Industries, Inc. | Pharmaceutical composition for treating and/or preventing cancer |
US9409993B2 (en) | 2011-08-04 | 2016-08-09 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of pancreatic cancer |
KR101979208B1 (ko) | 2011-08-04 | 2019-05-16 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방용 의약 조성물 |
HUE033628T2 (en) | 2011-08-04 | 2017-12-28 | Toray Industries | Method for detecting pancreatic cancer |
-
2011
- 2011-02-04 MX MX2012009000A patent/MX342291B/es active IP Right Grant
- 2011-02-04 WO PCT/JP2011/052412 patent/WO2011096533A1/ja active Application Filing
- 2011-02-04 RU RU2012137504/10A patent/RU2597971C2/ru active
- 2011-02-04 ES ES11739881.8T patent/ES2606173T3/es active Active
- 2011-02-04 KR KR1020127022752A patent/KR101801667B1/ko active IP Right Grant
- 2011-02-04 EP EP11739881.8A patent/EP2532366B1/en active Active
- 2011-02-04 JP JP2011510202A patent/JP5742713B2/ja active Active
- 2011-02-04 BR BR112012018951A patent/BR112012018951C8/pt active IP Right Grant
- 2011-02-04 CN CN201180017395.0A patent/CN102821789B/zh active Active
- 2011-02-04 PT PT117398818T patent/PT2532366T/pt unknown
- 2011-02-04 CA CA2788716A patent/CA2788716C/en active Active
- 2011-02-04 HU HUE11739881A patent/HUE030742T2/en unknown
- 2011-02-04 DK DK11739881.8T patent/DK2532366T3/da active
- 2011-02-04 AU AU2011211698A patent/AU2011211698B2/en active Active
- 2011-02-04 US US13/577,212 patent/US8937160B2/en active Active
- 2011-02-04 PL PL11739881T patent/PL2532366T3/pl unknown
Also Published As
Publication number | Publication date |
---|---|
CA2788716C (en) | 2019-06-18 |
AU2011211698B2 (en) | 2015-07-16 |
CN102821789B (zh) | 2016-03-02 |
HUE030742T2 (en) | 2017-06-28 |
US8937160B2 (en) | 2015-01-20 |
DK2532366T3 (da) | 2017-01-02 |
BR112012018951C8 (pt) | 2020-06-23 |
BR112012018951A8 (pt) | 2020-03-31 |
ES2606173T3 (es) | 2017-03-23 |
AU2011211698A1 (en) | 2012-08-23 |
MX2012009000A (es) | 2012-08-31 |
WO2011096533A1 (ja) | 2011-08-11 |
PL2532366T3 (pl) | 2017-02-28 |
EP2532366A1 (en) | 2012-12-12 |
CN102821789A (zh) | 2012-12-12 |
KR20130033347A (ko) | 2013-04-03 |
MX342291B (es) | 2016-09-23 |
JP5742713B2 (ja) | 2015-07-01 |
RU2012137504A (ru) | 2014-03-10 |
PT2532366T (pt) | 2016-12-20 |
KR101801667B1 (ko) | 2017-11-27 |
US20130045210A1 (en) | 2013-02-21 |
BR112012018951B8 (pt) | 2020-06-09 |
CA2788716A1 (en) | 2011-08-11 |
RU2597971C2 (ru) | 2016-09-20 |
BR112012018951B1 (pt) | 2020-05-12 |
EP2532366B1 (en) | 2016-09-07 |
EP2532366A4 (en) | 2013-12-04 |
JPWO2011096533A1 (ja) | 2013-06-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112012018951A2 (pt) | composição farmacêutica, combinação farmacêutica e método para o tratamento e\ou prevenção de um câncer e anticorpo | |
BR112012018947A8 (pt) | composição farmacêutica para o tratamento e/ou prevenção de um câncer, anticorpo, combinação farmacêutica e método para o tratamento e/ou prevenção de um câncer | |
BR112012018943A8 (pt) | medicamento e método para o tratamento e/ou prevenção de um câncer | |
HUE047006T2 (hu) | Anti-caprin-1 antitesteket tartalmazó gyógyászati kompozíció rák kezelésére és/vagy megelõzésére | |
BR112014002621A2 (pt) | anticorpo, composição farmacêutica, combinação farmacêutica, dna e método de tratamento | |
BRPI0811589A2 (pt) | Composição farmacêutica e método para tratar câncer | |
BRPI0922475A2 (pt) | composto, composição farmacêutica , método para tratar câncer, e, uso de um composto. | |
PL2532364T3 (pl) | Kompozycja farmaceutyczna zawierająca przeciwciała anty CAPRIN-1 do leczenia i/lub zapobiegania nowotworowi | |
BR112015002541A2 (pt) | composto, composição farmacêutica, uso de um composto, e, método para tratamento de hcv em um paciente. | |
BR112015001098A2 (pt) | composto, composição farmacêutica e método para o tratamento de uma condição de doença. | |
BR112015003397A2 (pt) | composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente. | |
BR112015004489A2 (pt) | composto, composição farmacêutica, e, métodos para tratar um distúrbio proliferativo e para sintetizar um composto | |
BR112014032053A2 (pt) | composto, composição farmacêutica, utilização de um composto, método para o tratamento de câncer e invenção | |
BR112015004547A8 (pt) | compostos, composição farmacêutica, uso de um composto e método para o tratamento ou melhoria do cãncer | |
BR112014011671A2 (pt) | composto, composição farmacêutica, método para o tratamento de uma doença ou condição, e, uso de um composto | |
BR112013014583A2 (pt) | composição farmacêutica, e, métodos para o tratamento de inflamação, para o tratamento da dor, e para preparar 3-metanossulfonilpropionitrila | |
BR112014032510A2 (pt) | composto, composição farmacêutica, método para tratar ou prevenir uma doença ou desordem, e, uso de um composto. | |
BR112012022879A2 (pt) | composto, composição farmacêutica, uso do composto e método de tratamento | |
BR112012004333A2 (pt) | composto, composição farmacêutica, e, método para o tratamento ou a prevenção de uma doença ou um distúrbio. | |
BRPI0919238A2 (pt) | métodos e composições para o tratamento de câncer | |
BRPI0909164A2 (pt) | método e composições para o tratamento de câncer | |
BR112014031896A2 (pt) | composto, composição farmacêutica, e, método para o tratamento de um distúrbio | |
BRPI1007972A2 (pt) | composições de combinação e métodos para o tratamento de câncer | |
BR112013014522A2 (pt) | anticorpo anti-cd20 afucosilado e seu uso, composição e método para tratamento de um paciente que sofre de câncer | |
BR112013004456A2 (pt) | composição para tratamento de planta, e, método para o tratamento de plantas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 04/02/2011, OBSERVADAS AS CONDICOES LEGAIS. |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: REF. RPI 2575 DE 12/05/2020 QUANTO AO ENDERECO E A PRIORIDADE UNIONISTA. |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: REF. RPI 2575 DE 12/05/2020 QUANTO A PRIORIDADE UNIONISTA |